Login Register Cart 0
Generic placeholder image

Current Psychiatry Research and Reviews

Editor-in-Chief

ISSN (Print): 2666-0822
ISSN (Online): 2666-0830

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Case Report

Case Report: Experience with Cariprazine in Organic Delusional Disorder in an Elderly with Concomitant Somatic Pathology, Brief Report

Author(s): Evgeny Darin*

Volume 20, Issue 1, 2024

Published on: 26 December, 2022

Page: [74 - 81] Pages: 8

DOI: 10.2174/2666082219666221206112951

Price: $65

Abstract

Background: Organic disorder remains one of the most pressing issues in practical psychiatry, especially a disorder dominated by persistent or recurrent delusions. The difficulty for practitioners is often due to the older age of patients and the burden of concomitant therapeutic diseases. Modern and potentially promising pharmacological drugs developed in recent years include partial agonists of D2 and D3 receptors. Currently, there are insufficient publications of studies on Cariprazine use in various disorders that are not associated with endogenous pathology.

Case Presentation: The author presented the results of the patient’s clinical examination with a complex of psychodiagnostic techniques, instrumental research methods, observation data in the department, and an analysis of the patient’s medical history. The paper describes the experience of treating a patient with the latest generation antipsychotic drug Cariprazine.

Results: The author presents a case report on Cariprazine therapy in a 71-year-old female patient with a persistent organic delusional disorder with concomitant severe somatic illness.

Conclusion: Cariprazine showed good efficacy in this case. Delusional symptoms were significantly reduced, and the author noted a reduction in negative symptoms. Mild side effects of the drug quickly resolved in the course of treatment.

The key point is that the description of this case may be relevant to justify the need for further clinical studies on Cariprazine. Further clinical studies of the drug in the treatment of various mental pathologies may be in demand by specialists around the world.

« Previous
[1]
Kekelidze ZI, Trushheljov SA. Format for presenting a clinical case report in the medical journal. Russ J Psychiatry 2017; 2: 54-8.
[2]
Darin E. Clinical case of organic pseudopsychopathic disorder in a teenager in terms of differential diagnostics with childhood schizophrenia. Curr Psychiatry Res Rev 2021; 17(1): 57-64.
[http://dx.doi.org/10.2174/2666082217666210208201756]
[3]
Darin EV, Ambartsumyan AR, Grigoreva EV, Zakharchenko YA, Korol IS. Report on a clinical case of phychotic manifestations in patients with organic disorder of mixed etiology. In: XLV International Scientific-Practical Conference "Modern Medicine, New Approaches, and Relevant Studies. 2019; p. 2.
[4]
Lawrence D, Kisely S, Pais J. The epidemiology of excess mortality in people with mental illness. Can J Psychiatry 2010; 55(12): 752-60.
[http://dx.doi.org/10.1177/070674371005501202] [PMID: 21172095]
[5]
Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21(10): 718-79.
[http://dx.doi.org/10.1016/j.euroneuro.2011.08.008] [PMID: 21924589]
[6]
Darin EV, Ambartsumyan AR, Pitel DA. Mortality structure among patients with various nosologic types of mental diseases. Literature review. Sci Herit 2021; 2(61): 29-34.
[7]
Darin EV. Mortality rates of patients diagnosed with mental and neurological disorders while using psychoactive substances. Narkologija 2021; 20(6): 61-8.
[8]
Gutzmann H, Krüger H, Neumann E-M. Organic, including symptomatic, mental disorders (sectionf0) - Results of the ICD-10 field trial. Pharmacopsychiatry 1990; 23(4): 146-50.
[9]
Smith RC, Leucht S, Davis JM. Maximizing response to first-line antipsychotics in schizophrenia: A review focused on finding from meta-analysis. Psychopharmacology 2019; 236(2): 545-59.
[http://dx.doi.org/10.1007/s00213-018-5133-z] [PMID: 30506237]
[10]
Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press 2021.
[http://dx.doi.org/10.1017/9781108975292]
[11]
Riva MA. Third-generation antipsychotics: Focus on cariprazine. Riv Psichiatr 2021; 56(2): 1-9.
[PMID: 34003178]
[12]
Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry 2018; 17(3): 341-56.
[http://dx.doi.org/10.1002/wps.20567] [PMID: 30192094]
[13]
Wichniak A, Samochowiec J, Szulc A, et al. The position statement of the Working Group of the Polish Psychiatric Association on the use of D2/D3 dopamine receptor partial agonists in the treatment of mental disorders. Psychiatr Pol 2021; 55(5): 941-66.
[http://dx.doi.org/10.12740/PP/138177] [PMID: 34997736]
[14]
Scott IA. The Lüscher Colour Test. Pan Books 1972.
[15]
Luria AR. Memorizing 10 words. Almanach of Psychic Tests 1995; 1: 92-4.
[16]
Wechsler D. Wechsler Adult Intelligence Scale-Revised (WAIS-R). Psychological Corporation 1981.
[17]
Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 1988; 56(6): 893-7.
[http://dx.doi.org/10.1037/0022-006X.56.6.893] [PMID: 3204199]
[18]
Beck AT, Steer RA. Internal consistencies of the original and revised beck depression inventory. J Clin Psychol 1984; 40(6): 1365-7.
[http://dx.doi.org/10.1002/1097-4679(198411)40:6<1365:AID-JCLP2270400615>3.0.CO;2-D] [PMID: 6511949]
[19]
Smets EMA, Garssen B, Bonke B, De Haes JCJM. The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39(3): 315-25.
[http://dx.doi.org/10.1016/0022-3999(94)00125-O] [PMID: 7636775]
[20]
Galea M, Woodward M. Mini-mental state examination (MMSE). Aust J Physiother 2005; 51(3): 198.
[http://dx.doi.org/10.1016/S0004-9514(05)70034-9] [PMID: 16187459]
[21]
Surana P, Symonds JD, Srivastava P, et al. Infantile spasms: Etiology, lead time and treatment response in a resource limited setting. Epilepsy Behav Rep 2020; 14: 100397.
[http://dx.doi.org/10.1016/j.ebr.2020.100397] [PMID: 33196034]
[22]
Supasitthumrong T, Bolea-Alamanac BM, Asmer S, Woo VL, Abdool PS, Davies SJC. Gabapentin and pregabalin to treat aggressivity in dementia: A systematic review and illustrative case report. Br J Clin Pharmacol 2019; 85(4): 690-703.
[http://dx.doi.org/10.1111/bcp.13844] [PMID: 30575088]
[23]
Ivanov SV, Smulevich AB, Voronova EI. New generation antipsychotic Cariprasin (Reagila) in the treatment of schisophrenia: spectrum of clinical effectiveness and safety. Psikhiatriya 2020; 18(4): 139-48.
[http://dx.doi.org/10.30629/2618-6667-2020-18-4-139-148]
[24]
Dyakov IN, Zyryanov SK. Clinical and economic efficiency of treatment with cariprazine in schizophrenia. Zh Nevrol Psikhiatr Im S S Korsakova 2019; 119(7): 69-77.
[http://dx.doi.org/10.17116/jnevro201911907169] [PMID: 31464292]
[25]
Cutler AJ, Durgam S, Wang Y, et al. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr 2018; 23(1): 39-50.
[http://dx.doi.org/10.1017/S1092852917000220] [PMID: 28478771]
[26]
Yachin KK, Orlov GV, Konovalova VN. Influence of an antipsychotic drug Cariprasin on a cognitive functioning of schisophrenic patients: Review on evidence-based studies of the drug. Curr Ther Men Disorder 2021.
[27]
Bandelow B, Schüller K. Mean age and gender distribution of patients with major mental disorders participating in clinical trials. Eur Arch Psychiatry Clin Neurosci 2020; 270(6): 655-9.
[http://dx.doi.org/10.1007/s00406-018-0972-5] [PMID: 30600352]
[28]
Nguyen TH, Atayee RS, Derry KL, Hirst J, Biondo A, Edmonds KP. Characteristics of hospitalized patients screening positive for delirium. Am J Hosp Palliat Care 2020; 37(2): 142-8.
[http://dx.doi.org/10.1177/1049909119867046] [PMID: 31362517]
[29]
Ferrari S, Mattei G, Marchi M, Galeazzi GM, Pingani L. Is consultation-liaison psychiatry ‘getting old’? how psychiatry referrals in the general hospital have changed over 20 years. Int J Environ Res Public Health 2020; 17(20): 7389.
[http://dx.doi.org/10.3390/ijerph17207389] [PMID: 33050480]
[30]
Loi S, Chiu E. Medical comorbidity in psychogeriatric patients. Curr Opin Psychiatry 2011; 24(4): 355-8.
[http://dx.doi.org/10.1097/YCO.0b013e3283454d9e] [PMID: 21378569]
[31]
Szatmári B, Barabássy Á, Harsányi J, et al. Cariprazine safety in adolescents and the elderly: Analyses of clinical study data. Front Psychiatry 2020; 11(61): 61.
[http://dx.doi.org/10.3389/fpsyt.2020.00061] [PMID: 32194443]
[32]
Citrome L. Cariprazine: Chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol 2013; 9(2): 193-206.
[http://dx.doi.org/10.1517/17425255.2013.759211] [PMID: 23320989]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy